# A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients

> **NCT03419975** · PHASE3 · COMPLETED · sponsor: **Taejoon Pharmaceutical Co., Ltd.** · enrollment: 146 (estimated)

## Conditions studied

- Primary Open-angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** TJO-002
- **DRUG:** Latanoprost

## Key facts

- **NCT ID:** NCT03419975
- **Lead sponsor:** Taejoon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-26
- **Primary completion:** 2017-12-28
- **Final completion:** 2018-06-01
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2019-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03419975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03419975, "A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03419975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*